224 related articles for article (PubMed ID: 36972373)
41. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G
Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238
[TBL] [Abstract][Full Text] [Related]
42. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
[TBL] [Abstract][Full Text] [Related]
43. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Tan X; Hu J
Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
[TBL] [Abstract][Full Text] [Related]
44. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Najafi S; Bahrami M; Butler AE; Sahebkar A
Br J Clin Pharmacol; 2022 Aug; 88(8):3627-3637. PubMed ID: 35384008
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
[TBL] [Abstract][Full Text] [Related]
46. New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.
Katsenos AP; Davri AS; Simos YV; Nikas IP; Bekiari C; Paschou SA; Peschos D; Konitsiotis S; Vezyraki P; Tsamis KI
Expert Opin Investig Drugs; 2022 Jan; 31(1):105-123. PubMed ID: 34941464
[TBL] [Abstract][Full Text] [Related]
47. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
48. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.
Gurgle HE; White K; McAdam-Marx C
Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752
[TBL] [Abstract][Full Text] [Related]
49. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
[TBL] [Abstract][Full Text] [Related]
50. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
51. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
[TBL] [Abstract][Full Text] [Related]
52. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
Battise DM; Olin JL
J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
[TBL] [Abstract][Full Text] [Related]
53. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.
Inzucchi SE
Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378
[TBL] [Abstract][Full Text] [Related]
54. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
[TBL] [Abstract][Full Text] [Related]
55. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Nassif ME; Kosiborod M
Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
[TBL] [Abstract][Full Text] [Related]
56. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
Kim GS; Park JH; Won JC
Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
[TBL] [Abstract][Full Text] [Related]
57. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
58. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
60. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
